Medicap Healthcare cut its IPO size by 29% to Rs 170 crore, according to an addendum published on November 21. The Gujarat-based firm also dropped its pre-IPO placement plans. The company said, "The proposed expansion will be undertaken by installing 29 additional injection molding machines at the existing manufacturing unit."
Market Mastery
Webinar by Vishal Malkan
Find the weak links
in your portfolio by Vishal Malkan
Gujarat-based pharmaceutical packaging company Medicap Healthcare has reduced the size of its initial public offering (IPO) by 29% and decided to drop the pre-IPO placement component from the revised offer structure, according to an addendum published on November 21.
In its notice to investors, the company said that, pursuant to a board resolution dated November 15, it had decided to reduce the issue size from Rs 240 crore, as disclosed in the draft red herring prospectus (DRHP), to Rs 170 crore. It also decided not to issue specified securities through a pre-IPO placement as part of the offering.
The revision is in line with SEBI regulations and related guidelines, which allow issuers to increase or decrease the fresh issue size by up to 50% without refiling the DRHP for IPOs opening on or before March 31, 2027.
Medicap Healthcare filed its draft offer document with the capital markets regulator in September 2025. Subsequently, SEBI approved the IPO papers in January 2026.
The proposed IPO initially comprised an entirely fresh issue, with no offer-for-sale (OFS) component. The fresh issue structure also included a proposed pre-IPO placement of Rs 48 crore.
The company, which operates a manufacturing facility in Vadodara, Gujarat, specialises in manufacturing pharmaceutical closures, including Euro Head caps and bottle preforms.
Following the reduction in the IPO size, Medicap Healthcare has also revised the proposed utilisation of the issue proceeds.
Of the net proceeds, Rs 83 crore will be used to purchase plant and machinery for its existing manufacturing facility, while Rs 44 crore will be allocated towards debt repayment. The remaining proceeds will be used for general corporate purposes.
In FY26, the company manufactured approximately 45 crore units against an installed production capacity of around 80 crore units at its existing manufacturing facility.
As part of its proposed expansion, Medicap Healthcare plans to increase the facility's installed annual production capacity by 69.6 crore units for pharmaceutical packaging caps and closures and 27 crore units for bottle preforms, taking the total additional capacity to 96.6 crore units per annum.
"The proposed expansion will be undertaken by installing 29 additional injection molding machines at the existing manufacturing unit," Medicap Healthcare said in its addendum.
Meanwhile, the company had outstanding borrowings of Rs 244.9 crore on a consolidated basis and Rs 36.2 crore on a standalone basis as of November 15, 2026.
Aryaman Financial Services has been appointed as the merchant banker for the Medicap Healthcare IPO.
